Clinical Trial Update: A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex [Phase 4]

View source ↗

Summary

Phase 4 study evaluating Epidiolex as add-on therapy for tuberous sclerosis complex–associated neuropsychiatric disease in ages 1 to 65, currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberous Sclerosis Complex
• Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

Drugs mentioned

• EPIDIOLEX (Cannabidiol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | Phase 4 | Status: ACTIVE_NOT_RECRUITING